ABSTRACT
Background Several inflammatory cytokines are upregulated in severe COVID-19. We compared cytokines in COVID-19 versus influenza in order to define differentiating features of the inflammatory response to these pathogens and their association with severe disease. Because elevated body mass index (BMI) is a known risk factor for severe COVID-19, we examined the relationship of BMI to cytokines associated with severe disease.
Methods Thirty-seven cytokines and chemokines were measured in plasma from 145 patients with COVID-19, 57 patients with influenza, and 30 healthy controls. Controlling for BMI, age, and sex, differences in cytokines between groups were determined by linear regression and random forest prediction was utilized to determine the cytokines most important in distinguishing severe COVID-19 and influenza. Mediation analysis was utilized to identify cytokines that mediate the effect of BMI on disease severity.
Results IL-18, IL-1β, IL-6, and TNF-α were significantly increased in COVID-19 versus influenza patients while GM-CSF, IFN-γ, IFN-λ1, IL-10, IL-15, and MCP-2 were significantly elevated in the influenza group. In subgroup analysis based on disease severity, IL-18, IL-6, and TNF-α were elevated in severe COVID-19, but not severe influenza. Random forest analysis identified high IL-6 and low IFN-λ1 levels as the most distinct between severe COVID-19 and severe influenza. Finally, IL-1RA was identified as a potential mediator of the effects of BMI on COVID-19 severity.
Conclusions These findings point to activation of fundamentally different innate immune pathways in SARS-CoV-2 and influenza infection, and emphasize drivers of severe COVID-19 to focus both mechanistic and therapeutic investigations.
Summary Severe COVID-19 is marked by dysregulated inflammation and is associated with elevated BMI. By comparing cytokines and chemokines in patients with either COVID-19 or influenza, we identified distinct inflammatory pathways and a cytokine mediator of the effect of BMI.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Johns Hopkins COVID-19 Research Response Program, a Johns Hopkins University Provost Research Grant, The Bill and Melinda Gates Foundation (134582), National Cancer Institute (U54CA260491), and National Institutes of Health Centers of Excellence in Influenza Research and Surveillance (HHSN272201400007C). The study was supported in part by a cooperative agreement between Johns Hopkins University (JHU) and the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA; agreement number IDSEP160031-01-00), the National Institute of Allergy and Infectious Diseases U19AI088791 and R01AI108403 and National Institute of Allergy and Infectious Diseases contract HHSN272201400007C awarded to Johns Hopkins Center of Excellence in Influenza Research and Surveillance (JHCEIRS). HJ and WZ were supported in part by the National Institute of Health grant R01HG009518. AHK was supported by the National Institute of Health T32 AI007291-27. AF was supported, in part, by grant D18HP29037 from the U.S. Health Resources and Services Administration, Bureau of Health Workforce, Health Careers Opportunity Program. RER was support in part by the National Institute of Allergy and Infectious Diseases contract HHSN272201400007C awarded to the Johns Hopkins Center of Excellence in Influenza Research and Surveillance (JHCEIRS) at the Johns Hopkins University and US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA; agreement number IDSEP160031-01-00).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies were approved by the Johns Hopkins (JH) Institutional Review Board. Hospitalized patients diagnosed with COVID-19 by positive SARS-CoV-2 RNA testing in the Johns Hopkins Healthcare System were enrolled in a prospective consented protocol to investigate research questions specific to the clinical course of COVID-19 (JH IRB 00245545). Plasma samples from hospitalized patients infected with influenza between 2017 and 2019 were obtained as previously described for comparison to hospitalized COVID-19 patients in this study [41,42], under an IRB approved protocol (JH IRB 00091667). The healthy control (HC) plasma samples were obtained from HIV/HCV-antibody seronegative subjects enrolled before 2020 in the Baltimore Before and After Acute Study of Hepatitis (BBAASH) study (JH IRB NA_00046368)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Anonymized data will be available upon reasonable request to the corresponding author.
